Navigation Links
New anti-cancer agents show promise for treating aggressive breast cancers
Date:7/18/2011

Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.

ABT-737 is one of a new class of anti-cancer agents called BH3 mimetics that target and neutralise the so-called Bcl-2 proteins in cancer cells. Bcl-2 proteins act to 'protect' the cells after they have been damaged by chemotherapy drugs, and prevent the cancer cells from dying.

Professors Geoff Lindeman and Jane Visvader, who led the research with colleagues Dr Samantha Oakes and Dr Franois Vaillant from the institute's Stem Cells and Cancer division, said that the BH3 mimetics showed promise for treating breast cancers, including 'triple negative' cancers. Their research is published today in the Proceedings of the National Academy of Sciences USA.

Triple negative breast cancers are so-called because they test negative for oestrogen, progesterone and HER2 receptors, and cannot be treated with hormone therapy or trastuzumab. They account for up to 20 per cent of all breast cancers and are typically aggressive with a poor prognosis.

Dr Lindeman said that early results suggest navitoclax (an orally-available BH3 mimetic) could provide new hope for treating some breast cancers that are not candidates for other currently available treatments.

"ABT-737 targets proteins from the Bcl-2 family, which are found at high levels in up to 70 per cent of breast cancers," Dr Lindeman said. "We have shown that breast tumours that have high levels of Bcl-2 respond well to treatment with ABT-737 when used in combination with a conventional chemotherapy drug."

ABT-737 and navitoclax were discovered by Abbott scientists and are based on the discovery made at the Walter and Eliza Hall Institute in the 1980s that Bcl-2 is a 'pro-survival' protein responsible for preventing cell death in healthy and diseased cells
'/>"/>

Contact: Liz Williams
williams@wehi.edu.au
61-405-279-095
Walter and Eliza Hall Institute
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Garden-Grown Rhubarb May Have Anti-Cancer Properties
2. Overcoming tumor resistance to anti-cancer agent TRAIL
3. UNC study offers first clinical evidence of anti-cancer drug triggering viral infection
4. ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
5. Program focuses on anti-cancer stem cell therapies
6. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
7. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
8. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
9. Researchers advance biosynthesis of potent anti-cancer drug Taxol
10. Parkinsons disease: Excess of special protein identified as key to symptoms and possible new target for treatment with widely used anti-cancer drug imatinib
11. Soft drink could enhance effects of an anti-cancer drug
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New anti-cancer agents show promise for treating aggressive breast cancers
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... a five-year, $1.24 million Science Education Partnership Award ... to support NAHN’s collaborative project with the Hispanic ... Health Careers. , This collaborative NIH R25 program ... cultural and linguistic diversity among health professionals by ...
(Date:8/20/2014)... New Jersey (PRWEB) August 20, 2014 ... meeting the needs of an estimated tens of thousands ... of the new Bill A3525—a bill that would expand ... to grow their own cannabis—earlier this summer by State ... training for medicinal quality marijuana is growing. , To ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Verndale is ... Inc. 500|5000 list; an exclusive list ranking the fastest-growing ... are ranked according to their yearly percentage revenue growth ... 8th time on the Inc. 5000 list where it ... Company, Verndale offers its clients a wide range of ...
(Date:8/20/2014)... B. E. Smith, the only full-service ... been retained to lead a national chief operating ... in Hermiston, Ore. The top executive search firm ... recently placed more than 900 healthcare executives into organizations. ... progressive, not-for-profit healthcare organization serving a population of more ...
(Date:8/20/2014)... Biosimilars, which are similar versions of ... abbreviated process, could reap billions in health care ... Inc.’s (AIS) Specialty Pharmacy News offers coverage of ... and Drug Administration’s (FDA) recent acceptance of a ... Drugmaker Sandoz said July 24 that the FDA ...
Breaking Medicine News(10 mins):Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:For the 8th Time, Verndale Has Been Honored on the Inc. 5000 List 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 2Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 3
... Company ... driving growth of EMR business, MARKHAM, ON, Feb. ... (TSX-V: NGH), one of North,America,s fastest growing healthcare software ... Helper business to Netsmart,Technologies Inc., a leading provider of ...
... a response in the adult brain , , FRIDAY, Feb. 29 ... ga-ga when they see a baby? , Scientists report ... up a specific region of the adult brain associated with ... looked at another adult face, suggesting there,s a neural basis ...
... BOTHELL, Wash., Feb. 29 Nastech,Pharmaceutical Company Inc. ... will,host a conference call with investors and security ... Eastern time (8:30 a.m. Pacific time) to,discuss the ... in the live conference call, U.S. residents should,dial ...
... quantify heritability of the disease , , FRIDAY, Feb. 29 (HealthDay ... chronic bronchitis, genes also play a major role in the ... which analyzed data on more than 40,000 twins born in ... percent of the risk for chronic bronchitis and that 14 ...
... published in the February issue of Injury Prevention estimates ... schools in 2005-2007 were directly related to an action ... or disciplinary committee. , Researchers in the Center for ... analyzed data from the 2005-2006 and 2006-2007 National High ...
... under 60 survived longer than people who had single ... double lung transplant leads to longer survival than a ... are in the final stages of chronic obstructive pulmonary ... lung transplants are both recognized as treatment options for ...
Cached Medicine News:Health News:Nightingale announces US$12.3 million sale of its Therapist Helper business 2Health News:Nightingale announces US$12.3 million sale of its Therapist Helper business 3Health News:Nightingale announces US$12.3 million sale of its Therapist Helper business 4Health News:Babies Really Can Light Up Your Life 2Health News:Babies Really Can Light Up Your Life 3Health News:Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss Corporate Restructuring and Future Strategy on Monday, March 3, 2008 2Health News:Genetic Factors for Smoking Boost Chronic Bronchitis Risk 2Health News:When the rules of the game are broken: Research studies sports injuries related to illegal activity 2Health News:Double Lung Transplant Better for Younger COPD Patients 2
(Date:8/19/2014)... MENLO PARK, Calif. , Aug. 19, 2014 ... company") announced today a protocol amendment to allow for expanded ... the U.S. Food and Drug Administration (FDA) and that a ... opened at three clinical trial sites in the ... proceeds of US$2.9 million have been raised through warrant exercise ...
(Date:8/19/2014)... 19, 2014 ,Weight Loss- Market ... 2014, report provides comprehensive insights about phase III pipeline ... objective of the report is to establish the understanding ... drugs across the different countries and regions. While the ... report also provides details on the drug master filings ...
(Date:8/18/2014)... and HERZLIYA-PITUACH, Israel , Aug. 19, 2014 ... North Premier, Stockholm : "IMNP"), a biotechnology ... application to list its common stock on the NASDAQ Capital ... unit of the NASDAQ OMX Group. IMMUNE,s common stock is ... the opening of trading on August 21, 2014 under the ...
Breaking Medicine Technology:DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4
... Dec. 27, 2011 Neuralstem, Inc. (NYSE Amex: ... Food and Drug Administration to advance to Phase Ib in ... NSI-189, for the treatment of major depressive disorder ... the drug in depressed patients. NSI-189 is a proprietary new ...
... Dec. 27, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical ... Botanic" or the "Company"), a developer, manufacturer and ... Medicines ("TCM") in China, today announced that the ... 66th PHARMCHINA fair ("the Fair") recently held in ...
Cached Medicine Technology:Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib 2Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib 3Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib 4China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair 2China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair 3
The Redi-glaze spectacle magnifier is an aspheric lens, glazed into a standard Keeler LVA frame....
This set is designed to introduce the low vision practitioner to the Keeler telescopic system....
... Featuring up to 20 ... examination in the vertical, ... plus the option to ... corneal transillumination., ,Filters include ...
Comes complete in its own carrying case. There are 24 lenses, 13mm diameter -6D to +6D in 0.5D steps. Mounted in tough, yet light alloy frame....
Medicine Products: